Melanie L. Graham

Dr. Melanie L. Graham

Department of Surgery, University of Minnesota, Minneapolis, USA
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BHBernhard J Hering
Bernhard J Hering
MWMartin Wijkstrom
Martin Wijkstrom
Melanie L. GrahamMelanie L. Graham
Melanie L. Graham
MHMaria Hårdstedt
Maria Hårdstedt
TATor C Aasheim
Tor C Aasheim
HSHenk-Jan Schuurman
Henk-Jan Schuurman

1 July 2015 in European Journal of Pharmacology
Verified
Journal Article
Open access
Melanie L. GrahamMelanie L. Graham
Melanie L. Graham
MPMark Prescott
Mark Prescott
Ethics on animal use in science in Western society is based on utilitarianism, weighing the harms and benefits to the animals involved against those of the intended human beneficiaries. The 3Rs concept (Replacement, Reduction, Refinement) is both a robust framework for minimizing animal use and suffering (addressing the harms to animals) and a means of supporting high quality science and translation (addressing the benefits). The ambiguity of basic research performed early in the research continuum can sometimes make harm-benefit analysis more difficult since anticipated benefit is often an incremental contribution to a field of knowledge. On the other hand, benefit is much more evident in translational research aimed at developing treatments for direct application in humans or animals suffering from disease. Though benefit may be easier to define, it should certainly not be considered automatic. Issues related to model validity seriously compromise experiments and have been implicated as a major impediment in translation, especially in complex disease models where harms to animals can be intensified. Increased investment and activity in the 3Rs is delivering new research models, tools and approaches with reduced reliance on animal use, improved animal welfare, and improved scientific and predictive value.

1 November 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ZSZeeshan Syedain
Zeeshan Syedain
Melanie L. GrahamMelanie L. Graham
Melanie L. Graham
TDTy B. Dunn
Ty B. Dunn
TOTimothy O’brien
Timothy O’brien
SJSandra L. Johnson
Sandra L. Johnson
RTRobert T. Tranquillo
Robert T. Tranquillo
A decellularized tissue tube grown from human skin cells and fibrin becomes repopulated by recipient cells when tested in baboons as a vascular graft for hemodialysis access.

1 August 2011
Verified
Journal Article
Closed access
Melanie L. GrahamMelanie L. Graham
Melanie L. Graham
JJJody L Janecek
Jody L Janecek
JKJessica A Kittredge
Jessica A Kittredge
BHBernhard J Hering
Bernhard J Hering
HSHenk-Jan Schuurman
Henk-Jan Schuurman

1 August 2018 in Transplantation
Verified
Journal Article
Closed access
JOJon Odorico
Jon Odorico
JMJames Markmann
James Markmann
DMDouglas Melton
Douglas Melton
JGJulia Greenstein
Julia Greenstein
AHAlbert Hwa
Albert Hwa
AAAnn Bfa Adams
Ann Bfa Adams
Beta cell replacement has the potential to restore euglycemia in patients with insulin-dependent diabetes. Although great progress has been made in establishing allogeneic islet transplantation from deceased donors as the standard of care for those with the most labile diabetes, it is also clear that the deceased donor organ supply cannot possibly treat all those who could benefit from restoration of a normal beta cell mass, especially if immunosuppression were not required. Against this background, the International Pancreas and Islet Transplant Association in collaboration with the Harvard Stem Cell Institute, the Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Foundation held a 2-day Key Opinion Leaders Meeting in Boston in 2016 to bring together experts in generating and transplanting beta cells derived from stem cells. The following summary highlights current technology, recent significant breakthroughs, unmet needs and roadblocks to stem cell–derived beta cell therapies, with the aim of spurring future preclinical collaborative investigations and progress toward the clinical application of stem cell–derived beta cells.

12 December 2011 in Journal of Medical Primatology
Verified
Journal Article
Closed access
PDF file
Melanie L. GrahamMelanie L. Graham
Melanie L. Graham
EREric F. Rieke
Eric F. Rieke
LMLucas A. Mutch
Lucas A. Mutch
EZElizabeth K. Zolondek
Elizabeth K. Zolondek
AFAaron W. Faig
Aaron W. Faig
HSHenk‐Jan Schuurman
Henk‐Jan Schuurman